ArticleHeart (British Cardiac Society)2026
Renal denervation for hypertension management in the UK: a Delphi expert consensus.
Article in Heart (British Cardiac Society), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal denervation (RDN) has emerged as a guideline-recommended therapeutic option in hypertension management with several high-quality, randomised, placebo-controlled trials demonstrating efficacy and safety. However, the lack of expert consensus on patient selection for RDN in the UK has led to debate regarding its use. This study aimed to establish a multidisciplinary consensus to provide clinicians and commissioners with guidance on the appropriate use of RDN in hypertension management within the UK.
methodsThe project used a modified Delphi method. A steering group (SG) of seven clinicians in cardiology, clinical pharmacology, radiology, nephrology and general practice, all experienced in managing patients with hypertension, convened in June 2024. The SG aligned on 40 consensus statements covering key topics (patient identification and selection, multidisciplinary team collaboration, commissioning and guidelines, training and education and awareness of RDN). The statements were distributed as an online survey to UK clinicians involved in hypertension management. Respondents assessed their level of agreement using a four-point Likert scale. Consensus was predefined as 75% agreement. The surveys were collated anonymously and independently analysed. The results were shared with the SG in November and December 2024.
resultsA total of 125 responses were received from interventional cardiologists and radiologists, cardiologists, clinical pharmacologists and nephrologists across various regions of the UK.Consensus was achieved for 37 out of 40 statements (93%). Based on the consensus scores, 11 key recommendations were developed by the SG regarding patient selection, multidisciplinary collaboration, clinician training and commissioning for RDN.
conclusionsThis expert consensus defines patient selection criteria for RDN and provides 11 recommendations to support its use. RDN should be considered for resistant hypertension or intolerance to medications, using a multidisciplinary approach. Implementation of these recommendations could guide clinical practice, inform commissioning and support National Institute for Health and Care Excellence reviews, ultimately improving patient access across the UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.